CDA-AMC recommends public reimbursement of LEQEMBI (lecanemab) for early Alzheimer’s disease
Eisai Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive recommendation for the public reimbursement of LEQEMBI (lecanemab) for eligible patients with early Alzheimer’s disease. The recommendation recognizes the therapy’s clinical value in slowing disease progression and helping patients remain in the early stages of Alzheimer’s disease for longer. The decision marks a significant step toward improving public access to Canada’s first disease-modifying treatment for early Alzheimer’s disease, with reimbursement discussions expected to proceed through participating public drug plans.
Aspen Pharmacare Canada receives Health Canada approval for generic equivalent of Ozempic (semaglutide injection)
Aspen Pharmacare Canada announced that Health Canada has approved Aspen-Semaglutide, a generic equivalent of Ozempic® (semaglutide injection), for improving glycemic control in adults with type 2 diabetes in combination with diet and exercise. Available in 2 mg and 4 mg pen formats, the generic is expected to expand access to semaglutide treatment options for Canadian patients. Commercial launch remains subject to the availability of active pharmaceutical ingredient (API) supply.
Devonian Health Group receives Health Canada authorization for pediatric Phase II/III Thykamine trial
Devonian Health Group announced that Health Canada has authorized the initiation of a Phase II/III clinical trial evaluating Thykamine for the treatment of mild-to-moderate atopic dermatitis in patients aged 3 months to 17 years. The trial will assess the safety and efficacy of the topical therapy in the pediatric population and supports the continued clinical development of Thykamine as a potential treatment option for children with atopic dermatitis.
Jupiter Neurosciences secures exclusive U.S. rights to ALA-002 under definitive licensing agreement
Jupiter Neurosciences announced it has signed a definitive licensing agreement with PharmAla Biotech for the exclusive U.S. rights to ALA-002, a next-generation MDMA-based therapeutic. The transaction is valued at up to US$100 million, including upfront consideration, development and commercial milestone payments, and future royalties. The agreement expands Jupiter’s central nervous system pipeline and supports the continued clinical development of ALA-002 for neuropsychiatric indications.
